RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Brazilian Regulators: Development, Oversight of Nanotechnology Products a Priority

Brazilian Regulators: Development, Oversight of Nanotechnology Products a Priority

Posted 05 November 2012 | By Ansis Helmanis

Brazil's National Health Surveillance Agency (Anvisa) met on 31 October 2012 to discuss the potential impact of nanotechnology on various fields, including medicines and biology, and how the technology could be used to benefit the country's national strategic priorities on public health and industrial development.

The use of nanotechnology has been associated with potential risks to human health, and Anvisa regulators made clear that the agency sees its role as both a facilitator of innovation and a protector of public health.

According to Agenor Álvares, a director at Anvisa, "The [agency] must continually monitor technological advances related to health, and Anvisa … has an important role in implementing these innovations."

Participants at the meeting included the Department of the Secretary of Innovative Technology of the Ministry of Development, the Industry and Foreign Trade Ministry, the Department of Technology Development, and the Oswaldo Cruz Foundation.


Read more:

Read all Breaking News from RegLink


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.